Compugen End Period Cash Flow Over Time
| CGEN Stock | USD 1.41 0.04 2.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Compugen Performance and Compugen Correlation. Compugen |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compugen. If investors know Compugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.03 | Revenue Per Share 0.48 | Quarterly Revenue Growth 3.461 | Return On Assets (0.03) | Return On Equity (0.16) |
The market value of Compugen is measured differently than its book value, which is the value of Compugen that is recorded on the company's balance sheet. Investors also form their own opinion of Compugen's value that differs from its market value or its book value, called intrinsic value, which is Compugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compugen's market value can be influenced by many factors that don't directly affect Compugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities End Period Cash Flow Analysis
Compare Compugen and related stocks such as Biomx Inc, Pluri Inc, and Surface Oncology End Period Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PHGE | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 8.7 M | 8.7 M | 37.2 M | 63.1 M | 32.3 M | 15.9 M | 27.2 M |
| PLUR | 961 | 9.4 M | 9 M | 4.5 M | 22.6 M | 6.2 M | 4.7 M | 8.8 M | 5.2 M | 9.2 M | 31.8 M | 11.4 M | 6.3 M | 7.7 M | 9.1 M |
| BLRX | 31.5 M | 8.7 M | 18.3 M | 8.9 M | 5.8 M | 5.5 M | 2.5 M | 5.1 M | 3.4 M | 5.3 M | 16.8 M | 13 M | 10.6 M | 4.3 M | 8 M |
| ITOS | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 20 M | 336.5 M | 848.8 M | 285 M | 251.5 M | 323.4 M |
| ANNX | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 44.2 M | 43.9 M | 268.6 M | 76 M | 141.1 M | 226.1 M | 126.2 M |
| ALLO | 93.7 M | 93.7 M | 93.7 M | 93.7 M | 93.7 M | 93.7 M | 93.7 M | 93.7 M | 93.7 M | 179.4 M | 192.8 M | 183.6 M | 72.2 M | 93.4 M | 108.7 M |
| BEAM | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 147.9 M | 50.6 M | 177 M | 572.7 M | 245.5 M | 435.9 M | 256.4 M |
| SANA | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 81.8 M | 126.9 M | 261.8 M | 187.3 M | 137.3 M | 151.4 M |
| CRBU | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 41.1 M | 16 M | 240.5 M | 58.4 M | 51.2 M | 89.6 M |
| EDIT | 6 M | 6 M | 6 M | 6 M | 10.6 M | 143.2 M | 185.3 M | 148.2 M | 136.4 M | 239.8 M | 143.6 M | 207.4 M | 145.4 M | 127.5 M | 149.3 M |
| CANF | 4.9 M | 3.8 M | 1.1 M | 6 M | 9.3 M | 16.9 M | 8.1 M | 3.5 M | 3.6 M | 2.7 M | 8.3 M | 4.4 M | 3 M | 4.3 M | 4.6 M |
| ICCC | 700 K | 781.5 K | 2.7 M | 2.3 M | 850 K | 1.6 M | 5.2 M | 3.8 M | 2.5 M | 6.3 M | 6.9 M | 10.2 M | 5.8 M | 978.7 K | 929.8 K |
| EVGN | 6.5 M | 6.5 M | 24.3 M | 95.5 M | 5.2 M | 10.2 M | 3.2 M | 3.4 M | 5.8 M | 34.7 M | 46.2 M | 32.3 M | 29 M | 20.8 M | 26.8 M |
| CLGN | 2.8 M | 2.8 M | 2.8 M | 6.8 M | 2.8 M | 1.4 M | 987.1 K | 5.1 M | 5.3 M | 4 M | 3.5 M | 13.4 M | 29.9 M | 26.7 M | 28 M |
Compugen and related stocks such as Biomx Inc, Pluri Inc, and Surface Oncology End Period Cash Flow description
My Equities
My Current Equities and Potential Positions
| Compugen | CGEN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Israel |
| Exchange | NASDAQ Exchange |
USD 1.41
Check out Compugen Performance and Compugen Correlation. To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Compugen technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.